Real-world clinical practice of intracoronary radiation therapy as compared to investigational trials

Seung-Woon Rha, Pramod K. Kuchulakanti, Rajbabu Pakala, Augusto D. Pichard, Lowell F. Satler, Kenneth M. Kent, William O. Suddath, Ellen Pinnow, Rebecca Torguson, Rosanna C. Chan, Regina Deible, Joseph Lindsay, Ron Waksman

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Intracoronary radiation therapy (IRT) is well established in clinical practice as an effective treatment for in-stent restenosis. We aimed to determine if the 6-month clinical outcome of patients treated postapproval for marketing [commercial radiation (CR)] is equivalent to those patients enrolled in the Washington Radiation for In-Stent Restenosis Trials [Gamma WRIST and Beta WRIST; investigational radiation (IR)]. The 6-month clinical outcome of 110 consecutive patients with 125 lesions who received IRT (gamma, 192Ir, 15-18 Gy, n = 6; or beta, 32P, 20 Gy, n = 20; or 90Sr/Y, 18.4-23.0 Gy, n = 99) in CR was compared with the 6-month clinical outcome of 117 patients with 117 lesions who received IRT (192Ir, 15 Gy, n = 65, in Gamma WRIST; and 90Y, 20.6 Gy, n = 52, in Beta WRIST) in IR. Patients in CR were treated with wider radiation margins. The CR received antiplatelet therapy for at least 6 months and the IR for 1 month. The baseline characteristics of both groups were similar. Use of atheroablation devices was less in CR than IR (15.2% vs. 32.8%, respectively; P = 0.001). The overall major adverse cardiac events (death, Q-wave myocardial infarction, and target vessel revascularization; 18.2% vs. 29.1% in IR; P = 0.05) were significantly lower in the CR when compared with patients in the IR. The real-world clinical practice of IRT demonstrates lower events and better clinical outcomes. This is most likely a result of implementation of the lessons learned from the clinical trials such as optimizing the dosimetry by using a higher dose, treating wider margins to minimize edge effect, and administering prolonged antiplatelet therapy to abolish late thrombosis.

Original languageEnglish
Pages (from-to)61-66
Number of pages6
JournalCatheterization and Cardiovascular Interventions
Volume64
Issue number1
DOIs
Publication statusPublished - 2005 Jan 1
Externally publishedYes

Fingerprint

Radiotherapy
Radiation
Stents
Marketing
Thrombosis
Therapeutics
Myocardial Infarction
Clinical Trials
Equipment and Supplies

Keywords

  • Brachytherapy
  • Restenosis
  • Revascularization

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Real-world clinical practice of intracoronary radiation therapy as compared to investigational trials. / Rha, Seung-Woon; Kuchulakanti, Pramod K.; Pakala, Rajbabu; Pichard, Augusto D.; Satler, Lowell F.; Kent, Kenneth M.; Suddath, William O.; Pinnow, Ellen; Torguson, Rebecca; Chan, Rosanna C.; Deible, Regina; Lindsay, Joseph; Waksman, Ron.

In: Catheterization and Cardiovascular Interventions, Vol. 64, No. 1, 01.01.2005, p. 61-66.

Research output: Contribution to journalArticle

Rha, S-W, Kuchulakanti, PK, Pakala, R, Pichard, AD, Satler, LF, Kent, KM, Suddath, WO, Pinnow, E, Torguson, R, Chan, RC, Deible, R, Lindsay, J & Waksman, R 2005, 'Real-world clinical practice of intracoronary radiation therapy as compared to investigational trials', Catheterization and Cardiovascular Interventions, vol. 64, no. 1, pp. 61-66. https://doi.org/10.1002/ccd.20234
Rha, Seung-Woon ; Kuchulakanti, Pramod K. ; Pakala, Rajbabu ; Pichard, Augusto D. ; Satler, Lowell F. ; Kent, Kenneth M. ; Suddath, William O. ; Pinnow, Ellen ; Torguson, Rebecca ; Chan, Rosanna C. ; Deible, Regina ; Lindsay, Joseph ; Waksman, Ron. / Real-world clinical practice of intracoronary radiation therapy as compared to investigational trials. In: Catheterization and Cardiovascular Interventions. 2005 ; Vol. 64, No. 1. pp. 61-66.
@article{e8b919316095490e9d1b2358788cbeb4,
title = "Real-world clinical practice of intracoronary radiation therapy as compared to investigational trials",
abstract = "Intracoronary radiation therapy (IRT) is well established in clinical practice as an effective treatment for in-stent restenosis. We aimed to determine if the 6-month clinical outcome of patients treated postapproval for marketing [commercial radiation (CR)] is equivalent to those patients enrolled in the Washington Radiation for In-Stent Restenosis Trials [Gamma WRIST and Beta WRIST; investigational radiation (IR)]. The 6-month clinical outcome of 110 consecutive patients with 125 lesions who received IRT (gamma, 192Ir, 15-18 Gy, n = 6; or beta, 32P, 20 Gy, n = 20; or 90Sr/Y, 18.4-23.0 Gy, n = 99) in CR was compared with the 6-month clinical outcome of 117 patients with 117 lesions who received IRT (192Ir, 15 Gy, n = 65, in Gamma WRIST; and 90Y, 20.6 Gy, n = 52, in Beta WRIST) in IR. Patients in CR were treated with wider radiation margins. The CR received antiplatelet therapy for at least 6 months and the IR for 1 month. The baseline characteristics of both groups were similar. Use of atheroablation devices was less in CR than IR (15.2{\%} vs. 32.8{\%}, respectively; P = 0.001). The overall major adverse cardiac events (death, Q-wave myocardial infarction, and target vessel revascularization; 18.2{\%} vs. 29.1{\%} in IR; P = 0.05) were significantly lower in the CR when compared with patients in the IR. The real-world clinical practice of IRT demonstrates lower events and better clinical outcomes. This is most likely a result of implementation of the lessons learned from the clinical trials such as optimizing the dosimetry by using a higher dose, treating wider margins to minimize edge effect, and administering prolonged antiplatelet therapy to abolish late thrombosis.",
keywords = "Brachytherapy, Restenosis, Revascularization",
author = "Seung-Woon Rha and Kuchulakanti, {Pramod K.} and Rajbabu Pakala and Pichard, {Augusto D.} and Satler, {Lowell F.} and Kent, {Kenneth M.} and Suddath, {William O.} and Ellen Pinnow and Rebecca Torguson and Chan, {Rosanna C.} and Regina Deible and Joseph Lindsay and Ron Waksman",
year = "2005",
month = "1",
day = "1",
doi = "10.1002/ccd.20234",
language = "English",
volume = "64",
pages = "61--66",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Real-world clinical practice of intracoronary radiation therapy as compared to investigational trials

AU - Rha, Seung-Woon

AU - Kuchulakanti, Pramod K.

AU - Pakala, Rajbabu

AU - Pichard, Augusto D.

AU - Satler, Lowell F.

AU - Kent, Kenneth M.

AU - Suddath, William O.

AU - Pinnow, Ellen

AU - Torguson, Rebecca

AU - Chan, Rosanna C.

AU - Deible, Regina

AU - Lindsay, Joseph

AU - Waksman, Ron

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Intracoronary radiation therapy (IRT) is well established in clinical practice as an effective treatment for in-stent restenosis. We aimed to determine if the 6-month clinical outcome of patients treated postapproval for marketing [commercial radiation (CR)] is equivalent to those patients enrolled in the Washington Radiation for In-Stent Restenosis Trials [Gamma WRIST and Beta WRIST; investigational radiation (IR)]. The 6-month clinical outcome of 110 consecutive patients with 125 lesions who received IRT (gamma, 192Ir, 15-18 Gy, n = 6; or beta, 32P, 20 Gy, n = 20; or 90Sr/Y, 18.4-23.0 Gy, n = 99) in CR was compared with the 6-month clinical outcome of 117 patients with 117 lesions who received IRT (192Ir, 15 Gy, n = 65, in Gamma WRIST; and 90Y, 20.6 Gy, n = 52, in Beta WRIST) in IR. Patients in CR were treated with wider radiation margins. The CR received antiplatelet therapy for at least 6 months and the IR for 1 month. The baseline characteristics of both groups were similar. Use of atheroablation devices was less in CR than IR (15.2% vs. 32.8%, respectively; P = 0.001). The overall major adverse cardiac events (death, Q-wave myocardial infarction, and target vessel revascularization; 18.2% vs. 29.1% in IR; P = 0.05) were significantly lower in the CR when compared with patients in the IR. The real-world clinical practice of IRT demonstrates lower events and better clinical outcomes. This is most likely a result of implementation of the lessons learned from the clinical trials such as optimizing the dosimetry by using a higher dose, treating wider margins to minimize edge effect, and administering prolonged antiplatelet therapy to abolish late thrombosis.

AB - Intracoronary radiation therapy (IRT) is well established in clinical practice as an effective treatment for in-stent restenosis. We aimed to determine if the 6-month clinical outcome of patients treated postapproval for marketing [commercial radiation (CR)] is equivalent to those patients enrolled in the Washington Radiation for In-Stent Restenosis Trials [Gamma WRIST and Beta WRIST; investigational radiation (IR)]. The 6-month clinical outcome of 110 consecutive patients with 125 lesions who received IRT (gamma, 192Ir, 15-18 Gy, n = 6; or beta, 32P, 20 Gy, n = 20; or 90Sr/Y, 18.4-23.0 Gy, n = 99) in CR was compared with the 6-month clinical outcome of 117 patients with 117 lesions who received IRT (192Ir, 15 Gy, n = 65, in Gamma WRIST; and 90Y, 20.6 Gy, n = 52, in Beta WRIST) in IR. Patients in CR were treated with wider radiation margins. The CR received antiplatelet therapy for at least 6 months and the IR for 1 month. The baseline characteristics of both groups were similar. Use of atheroablation devices was less in CR than IR (15.2% vs. 32.8%, respectively; P = 0.001). The overall major adverse cardiac events (death, Q-wave myocardial infarction, and target vessel revascularization; 18.2% vs. 29.1% in IR; P = 0.05) were significantly lower in the CR when compared with patients in the IR. The real-world clinical practice of IRT demonstrates lower events and better clinical outcomes. This is most likely a result of implementation of the lessons learned from the clinical trials such as optimizing the dosimetry by using a higher dose, treating wider margins to minimize edge effect, and administering prolonged antiplatelet therapy to abolish late thrombosis.

KW - Brachytherapy

KW - Restenosis

KW - Revascularization

UR - http://www.scopus.com/inward/record.url?scp=19944426617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944426617&partnerID=8YFLogxK

U2 - 10.1002/ccd.20234

DO - 10.1002/ccd.20234

M3 - Article

VL - 64

SP - 61

EP - 66

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 1

ER -